Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Endo Withdraws Opana Painkiller From Market at FDA’s Request

  • Post author:Sam
  • Post published:July 6, 2017
  • Post category:Drug Industry Daily

Endo will withdraw Opana ER from the market, following an FDA request in June. Source: Drug Industry Daily

Continue ReadingEndo Withdraws Opana Painkiller From Market at FDA’s Request

AAM: Patients Nearly 3 Times More Likely to Not Pick Up Branded Drugs

  • Post author:Sam
  • Post published:July 6, 2017
  • Post category:Generic Line

Patients are 266 percent more likely to not pick up brand-name medications after requesting them at a pharmacy, compared to generic prescriptions, according to the Association for Accessible Medicine’s annual…

Continue ReadingAAM: Patients Nearly 3 Times More Likely to Not Pick Up Branded Drugs

FDA Rejects Coherus’ Neulasta Biosimilar, Calls for New Analyses

  • Post author:Sam
  • Post published:July 6, 2017
  • Post category:Generic Line

The FDA rejected Coherus Bioscience’s proposed biosimilar for Amgen’s Neulasta, Coherus announced. Source: Generic Line

Continue ReadingFDA Rejects Coherus’ Neulasta Biosimilar, Calls for New Analyses

Jury Awards GSK $235M After Teva Adds CHF Indication to Coreg Label

  • Post author:Sam
  • Post published:July 6, 2017
  • Post category:Generic Line

A federal jury awarded GlaxoSmithKline $235 million in a suit against Teva, saying the generics manufacturer infringed on GSK’s patent for the cardiovascular drug Coreg when Teva marketed its generic…

Continue ReadingJury Awards GSK $235M After Teva Adds CHF Indication to Coreg Label

WHO Essential Medicines List Adds Drugs for Hep C, HIV & New Antibiotics

  • Post author:Sam
  • Post published:July 6, 2017
  • Post category:Generic Line

The World Health Organization published its biennial update to its list of essential medicines, adding therapies for hepatitis C, HIV and leukemia, as well as new advice on combating antimicrobial…

Continue ReadingWHO Essential Medicines List Adds Drugs for Hep C, HIV & New Antibiotics

PTAB Nixes Two More Humira Dosing Patents Following Coherus’ Challenges

  • Post author:Sam
  • Post published:July 6, 2017
  • Post category:Generic Line

The PTO invalidated two more AbbVie patents on dosing regimens for Humira after continuing challenges from Coherus, which plans to submit its biosimilar version of the blockbuster drug for FDA…

Continue ReadingPTAB Nixes Two More Humira Dosing Patents Following Coherus’ Challenges

CBO Scores User Fee Reauthorization Package

  • Post author:Sam
  • Post published:July 6, 2017
  • Post category:Generic Line

The Congressional Budget Office officially scored the Senate bill reauthorizing the FDA’s user fee agreements, saying it would add $740 million to the budget and a negligible amount to the…

Continue ReadingCBO Scores User Fee Reauthorization Package

University of Pennsylvania Installs Second Milabs Ultra-High Resolution Preclinical Imaging System

  • Post author:Sam
  • Post published:July 5, 2017
  • Post category:BioPharma

  Life Sciences Jobs   ... Source: BioSpace

Continue ReadingUniversity of Pennsylvania Installs Second Milabs Ultra-High Resolution Preclinical Imaging System

What Does It Take to Get Hired by GlaxoSmithKline and AbbVie

  • Post author:Sam
  • Post published:July 5, 2017
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x430-glaxosmithkline-abbvie.jpg" NAME"What Does It Take to Get Hired by GlaxoSmithKline and AbbVie" ALT"What Does It Take to Get Hired by GlaxoSmithKline and AbbVie"July 6, 2017By Mark Terry, BioSpace.com Breaking…

Continue ReadingWhat Does It Take to Get Hired by GlaxoSmithKline and AbbVie

Inventiva Announces First-Half 2017 Financial And Corporate Update

  • Post author:Sam
  • Post published:July 5, 2017
  • Post category:BioPharma

  Life Sciences Jobs   ... Source: BioSpace

Continue ReadingInventiva Announces First-Half 2017 Financial And Corporate Update
  • Go to the previous page
  • 1
  • …
  • 395
  • 396
  • 397
  • 398
  • 399
  • 400
  • 401
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.